Table 2.
Patients’ characteristics.
| Characteristic | N (%) |
|---|---|
| Sex | |
| Male | 36 (61) |
| Female | 23 (39) |
| Age | |
| Primary disease diagnosis (median years; IQR) | 58; (49–70) |
| Initiation of combined immunotherapy (median years; IQR) | 61; (51–74) |
| Melanoma subtype | |
| Cutaneous melanoma | 35 (59.3) |
| Acral melanoma | 6 (10.2) |
| Mucosal melanoma | 4 (6.7) |
| Melanoma of unknown primary | 5 (8.5) |
| Uveal melanoma | 9 (15.3) |
| Tumor mutation burden* (n = 56) | |
| TMB (mut/Mb median; IQR) | 4.7; (1.7–13.97) |
| Intermediate-low (≤23.1 mut/Mb) | 46 (82.1) |
| High (>23.1 mut/Mb) | 10 (17.9) |
| Serum biomarkers | |
| LDH | |
| Normal | 34 (57.6) |
| Elevated | 25 (42.4) |
| S100B* (n = 55) | |
| Normal | 22 (40) |
| Elevated | 33 (60) |
| BRAF mutation* (n = 57) | |
| Yes | 29 (50.9) |
| No | 28 (49.1) |
| Metastasis at start of nivolumab plus ipilimumab | |
| Presence of cerebral metastasis | 24 (40.7) |
| Presence of liver metastasis | 17 (28.8) |
| Presence of lung metastasis | 32 (54.2) |
| Nivolumab plus ipilimumab | |
| First line | 29 (49.2) |
| Second line or more | 30 (50.8) |
|
Response to nivolumab and ipilimumab at first staging* (n = 55) |
|
| Progressive disease | 34 (61.8) |
| Disease control | 21 (38.2) |
* Denotes variables for which patients with missing values were excluded.